ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
CONTENT TYPES

Design and Synthesis of Tricyclic Corticotropin-Releasing Factor-1 Antagonists

View Author Information
Departments of Medicinal Chemistry, Pharmacology and Lead Discovery, and Preclinical Development, Neurocrine Biosciences, 12790 El Camino Real, San Diego, California 92130
Cite this: J. Med. Chem. 2005, 48, 18, 5780–5793
Publication Date (Web):August 10, 2005
https://doi.org/10.1021/jm049085v
Copyright © 2005 American Chemical Society

    Article Views

    2282

    Altmetric

    -

    Citations

    LEARN ABOUT THESE METRICS
    Other access options
    Supporting Info (1)»

    Abstract

    Abstract Image

    Antagonists of the corticotropin-releasing factor (CRF) neuropeptide should prove to be effective in treating stress and anxiety-related disorders. In an effort to identify antagonists with improved physicochemical properties, new tricyclic CRF1 antagonists were designed, synthesized, and tested for biological activity. As a result of studies aimed at establishing a relationship between structure and CRF1 binding affinity, NBI 35965 (12a) was identified as a high-affinity antagonist with a pKi value of 8.5. Compound 12a proved to be a functional CRF1 antagonist with pIC50 values of 7.1 and 6.9 in the in vitro CRF-stimulated cAMP accumulation and ACTH production assays, respectively, and 12a also reduced CRF or stress induced ACTH production in vivo.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.

    Recommended

    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    #

     Department of Medicinal Chemistry.

     Department of Pharmacology and Lead Discovery.

     Department of Preclinical Development.

    *

     To whom correspondence should be addressed. Phone:  858-617-7662. Fax:  858-617-7619. E-mail:  [email protected].

    Supporting Information Available

    ARTICLE SECTIONS
    Jump To

    Tables of HPLC purity and elemental analyses. This material is available free of charge via the Internet at http://pubs.acs.org.

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.

    Cited By

    This article is cited by 40 publications.

    1. Hao Chen, Shanshan Deng, Najah Albadari, Mi-Kyung Yun, Sicheng Zhang, Yong Li, Dejian Ma, Deanna N. Parke, Lei Yang, Tiffany N. Seagroves, Stephen W. White, Duane D. Miller, Wei Li. Design, Synthesis, and Biological Evaluation of Stable Colchicine-Binding Site Tubulin Inhibitors 6-Aryl-2-benzoyl-pyridines as Potential Anticancer Agents. Journal of Medicinal Chemistry 2021, 64 (16) , 12049-12074. https://doi.org/10.1021/acs.jmedchem.1c00715
    2. Federica Bertolotti, Angelo Maspero, Antonio Cervellino, Antonietta Guagliardi, and Norberto Masciocchi . Bending by Faulting: A Multiple Scale Study of Copper and Silver Nitropyrazolates. Crystal Growth & Design 2014, 14 (6) , 2913-2922. https://doi.org/10.1021/cg500108g
    3. Valentina Colombo, Carmen Montoro, Angelo Maspero, Giovanni Palmisano, Norberto Masciocchi, Simona Galli, Elisa Barea, and Jorge A. R. Navarro . Tuning the Adsorption Properties of Isoreticular Pyrazolate-Based Metal–Organic Frameworks through Ligand Modification. Journal of the American Chemical Society 2012, 134 (30) , 12830-12843. https://doi.org/10.1021/ja305267m
    4. Subash Velaparthi, Michael Brunsteiner, Reaz Uddin, Baojie Wan, Scott G. Franzblau and Pavel A. Petukhov. 5-tert-Butyl-N-pyrazol-4-yl-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide Derivatives as Novel Potent Inhibitors of Mycobacterium tuberculosis Pantothenate Synthetase: Initiating a Quest for New Antitubercular Drugs. Journal of Medicinal Chemistry 2008, 51 (7) , 1999-2002. https://doi.org/10.1021/jm701372r
    5. Soumik Saha, Abigail B. Pinheiro, Amrita Chatterjee, Zigmee T. Bhutia, Mainak Banerjee. A solvent-free mechanochemical electrophilic C–H thiocyanation of indoles and imidazo[1,2- a ]pyridines using a cost-effective combination of N -chlorosuccinimide-NaSCN and tandem C–C and C–S bond formation. Green Chemistry 2024, 26 (10) , 5879-5889. https://doi.org/10.1039/D4GC00486H
    6. Elena Reinhardt, Tobias Lenz, Lukas Bauer, Jörg Stierstorfer, Thomas M. Klapötke. Synthesis and Characterization of Azido- and Nitratoalkyl Nitropyrazoles as Potential Melt-Cast Explosives. Molecules 2023, 28 (18) , 6489. https://doi.org/10.3390/molecules28186489
    7. Kai Lv, Shuo Wu, Zeyu Tao, Aoyu Wang, Shijie Xu, Lu Yang, Qiang Gao, Apeng Wang, Xiaoyu Qin, Bin Jiang, Wenhao Wu, Xuedong Jia, Yuhuan Li, Jiandong Jiang, Mingliang Liu. Identification of (6S)-cyclopropyl-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxamines as new HBV capsid assembly modulators. European Journal of Medicinal Chemistry 2022, 228 , 113974. https://doi.org/10.1016/j.ejmech.2021.113974
    8. Yuan Yin, Cheng-Juan Chen, Ru-Nan Yu, Lei Shu, Tian-Tai Zhang, Da-Yong Zhang. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold. Bioorganic & Medicinal Chemistry 2019, 27 (8) , 1562-1576. https://doi.org/10.1016/j.bmc.2019.02.054
    9. Mohamed Teleb, Bhimanna Kuppast, Katerina Spyridaki, George Liapakis, Hesham Fahmy. Synthesis of 2-imino and 2-hydrazono thiazolo[4,5- d ]pyrimidines as corticotropin releasing factor (CRF) antagonists. European Journal of Medicinal Chemistry 2017, 138 , 900-908. https://doi.org/10.1016/j.ejmech.2017.07.016
    10. E.P. Zorrilla. Corticotropin-Releasing Factor Receptor Antagonists. 2017, 265-277. https://doi.org/10.1016/B978-0-12-802175-0.00026-7
    11. Cristina Maccallini, Mauro Di Matteo, Daniela Vullo, Alessandra Ammazzalorso, Simone Carradori, Barbara De Filippis, Marialuigia Fantacuzzi, Letizia Giampietro, Assunta Pandolfi, Claudiu T. Supuran, Rosa Amoroso. Indazole, Pyrazole, and Oxazole Derivatives Targeting Nitric Oxide Synthases and Carbonic Anhydrases. ChemMedChem 2016, 11 (16) , 1695-1699. https://doi.org/10.1002/cmdc.201600204
    12. Xuewu Liang, Yongxue Huang, Jie Zang, Qianwen Gao, Binghe Wang, Wenfang Xu, Yingjie Zhang. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors. Bioorganic & Medicinal Chemistry 2016, 24 (12) , 2660-2672. https://doi.org/10.1016/j.bmc.2016.04.030
    13. John P Williams. Corticotropin-releasing factor 1 receptor antagonists: a patent review. Expert Opinion on Therapeutic Patents 2013, 23 (8) , 1057-1068. https://doi.org/10.1517/13543776.2013.795545
    14. Jiaheng Zhang, Chunlin He, Damon A. Parrish, Jean'ne M. Shreeve. Nitramines with Varying Sensitivities: Functionalized Dipyrazolyl‐ N ‐nitromethanamines as Energetic Materials. Chemistry – A European Journal 2013, 19 (27) , 8929-8936. https://doi.org/10.1002/chem.201300747
    15. Shigeyuki Chaki, Kosuke Kanuma. Neuropeptide Receptors: Novel Therapeutic Targets for Depression and Anxiety Disorders. 2012, 300-330. https://doi.org/10.1039/9781849734943-00300
    16. Beth A. Fleck, Sam R. J. Hoare, Rebecca R. Pick, Margaret J. Bradbury, Dimitri E. Grigoriadis. Binding Kinetics Redefine the Antagonist Pharmacology of the Corticotropin-Releasing Factor Type 1 Receptor. Journal of Pharmacology and Experimental Therapeutics 2012, 341 (2) , 518-531. https://doi.org/10.1124/jpet.111.188714
    17. Elisabetta Perdonà, Roberto Arban, Cristiana Griffante. Distinct receptor subtypes mediate arginine vasopressin-dependent ACTH release and intracellular calcium mobilization in rat pituitary cells. European Journal of Pharmacology 2012, 679 (1-3) , 16-23. https://doi.org/10.1016/j.ejphar.2012.01.003
    18. B. V. Lyalin, V. A. Petrosyan. Effect of “anomalous” electrochemical halogenation of pyrazoles and its reasons. Russian Chemical Bulletin 2012, 61 (1) , 209-210. https://doi.org/10.1007/s11172-012-0030-9
    19. Maloy Nayak, Sanjay Batra. Synthesis of substituted pyrazolo[4,3-b]pyridines via copper-mediated intramolecular C–N cross-coupling of primary allylamines. RSC Advances 2012, 2 (8) , 3367. https://doi.org/10.1039/c2ra01170k
    20. Tetsuji Saito, Tetsuo Obitsu, Takashi Kondo, Toshiaki Matsui, Yuuki Nagao, Kensuke Kusumi, Naoya Matsumura, Sonoko Ueno, Akihiro Kishi, Seishi Katsumata, Yoshifumi Kagamiishi, Hisao Nakai, Masaaki Toda. 6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists. Bioorganic & Medicinal Chemistry 2011, 19 (18) , 5432-5445. https://doi.org/10.1016/j.bmc.2011.07.055
    21. Hala F. Rizk, Mahmoud A. EI‐Badawi, Seham A. Ibrahim, Mohamed A. EI‐Borai. Cyclization of 4,5‐Diamino Pyrazole Derivatives and Their Antibacterial Activities. Chinese Journal of Chemistry 2011, 29 (7) , 1451-1459. https://doi.org/10.1002/cjoc.201180265
    22. Marcelo Paez-Pereda, Felix Hausch, Florian Holsboer. Corticotropin releasing factor receptor antagonists for major depressive disorder. Expert Opinion on Investigational Drugs 2011, 20 (4) , 519-535. https://doi.org/10.1517/13543784.2011.565330
    23. John E. Tellew, Marion Lanier, Manisha Moorjani, Emily Lin, Zhiyong Luo, Deborah H. Slee, Xiaohu Zhang, Sam R.J. Hoare, Dimitri E. Grigoriadis, Yves St. Denis, Romano Di Fabio, Enza Di Modugno, John Saunders, John P. Williams. Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties. Bioorganic & Medicinal Chemistry Letters 2010, 20 (24) , 7259-7264. https://doi.org/10.1016/j.bmcl.2010.10.095
    24. Supriyo Bhattacharya, Govindan Subramanian, Spencer Hall, Jianping Lin, Abdelazize Laoui, Nagarajan Vaidehi. Allosteric antagonist binding sites in class B GPCRs: corticotropin receptor 1. Journal of Computer-Aided Molecular Design 2010, 24 (8) , 659-674. https://doi.org/10.1007/s10822-010-9364-2
    25. Marco De Amici, Clelia Dallanoce, Ulrike Holzgrabe, Christian Tränkle, Klaus Mohr. Allosteric ligands for G protein-coupled receptors: A novel strategy with attractive therapeutic opportunities. Medicinal Research Reviews 2010, 30 (3) , 463-549. https://doi.org/10.1002/med.20166
    26. Yingda Ye, Qinghua Liao, Jing Wei, Qingzhi Gao. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design. Neurochemistry International 2010, 56 (1) , 107-117. https://doi.org/10.1016/j.neuint.2009.09.008
    27. Jerome F. Hayes, Matthew E. Popkin. A Novel Synthesis of a 1,3-Disubstituted 1,3-Dihydro-2H-imidazo[4,5-b]pyridin-2-one. Application to GW808990 a CRF1 Receptor Antagonist. HETEROCYCLES 2010, 82 (1) , 297. https://doi.org/10.3987/COM-10-S(E)62
    28. Ted Kamenecka, Jeff Habel, Derek Duckett, Weimin Chen, Yuan Yuan Ling, Bozena Frackowiak, Rong Jiang, Youseung Shin, Xinyi Song, Philip LoGrasso. Structure-Activity Relationships and X-ray Structures Describing the Selectivity of Aminopyrazole Inhibitors for c-Jun N-terminal Kinase 3 (JNK3) over p38. Journal of Biological Chemistry 2009, 284 (19) , 12853-12861. https://doi.org/10.1074/jbc.M809430200
    29. Stephen R. Slauson, John M. Rimoldi, Frank R. Fronczek. Antalarmin. Acta Crystallographica Section E Structure Reports Online 2008, 64 (8) , o1650-o1651. https://doi.org/10.1107/S1600536808023775
    30. Sam R. J. Hoare, Beth A. Fleck, Raymond S. Gross, Paul D. Crowe, John P. Williams, Dimitri E. Grigoriadis. Allosteric Ligands for the Corticotropin Releasing Factor Type 1 Receptor Modulate Conformational States Involved in Receptor Activation. Molecular Pharmacology 2008, 73 (5) , 1371-1380. https://doi.org/10.1124/mol.107.042978
    31. Florian Holsboer, Marcus Ising. Central CRH system in depression and anxiety — Evidence from clinical studies with CRH1 receptor antagonists. European Journal of Pharmacology 2008, 583 (2-3) , 350-357. https://doi.org/10.1016/j.ejphar.2007.12.032
    32. B.R. Buckley. Bicyclic 5-6 Systems: Three Heteroatoms 2:1. 2008, 431-491. https://doi.org/10.1016/B978-008044992-0.00908-1
    33. R.L. Riggs, D.M. Smith. Three Heterocyclic Rings Fused (5-6-6). 2008, 857-973. https://doi.org/10.1016/B978-008044992-0.01117-2
    34. Carolyn D. Dzierba, Richard A. Hartz, Joanne J. Bronson. Chapter 1 Recent Advances in Corticotropin-Releasing Factor Receptor Antagonists. 2008, 3-23. https://doi.org/10.1016/S0065-7743(08)00001-8
    35. E. S. Komarova, V. A. Makarov, L. M. Alekseeva, G. V. Avramenko, V. G. Granik. 4,5-Diamino-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-b]pyridin-6-one in the synthesis of fused tricyclic systems. Russian Chemical Bulletin 2007, 56 (11) , 2337-2343. https://doi.org/10.1007/s11172-007-0369-5
    36. Marcus Ising, Ulrich S Zimmermann, Heike E Künzel, Manfred Uhr, Alan C Foster, Susan M Learned-Coughlin, Florian Holsboer, Dimitri E Grigoriadis. High-Affinity CRF1 Receptor Antagonist NBI-34041: Preclinical and Clinical Data Suggest Safety and Efficacy in Attenuating Elevated Stress Response. Neuropsychopharmacology 2007, 32 (9) , 1941-1949. https://doi.org/10.1038/sj.npp.1301328
    37. Dimitri E. Grigoriadis, Samuel R. J. Hoare. Emerging Anxiolytics: Corticotropin‐Releasing Factor Receptor Antagonists. 2007https://doi.org/10.1002/9780470101001.hcn027
    38. Heidi L. Fraser, M. Brawner Floyd, Darrin W. Hopper. Six-membered ring systems: pyridines and benzo derivatives. 2007, 310-351. https://doi.org/10.1016/S0959-6380(07)80016-X
    39. Sam R.J. Hoare, Brock T. Brown, Mark A. Santos, Siobhan Malany, Stephen F. Betz, Dimitri E. Grigoriadis. Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor1 (CRF1) receptor. Biochemical Pharmacology 2006, 72 (2) , 244-255. https://doi.org/10.1016/j.bcp.2006.04.007
    40. Deborah A. Evrard. Recent Strategies for the Development of New Antidepressant Drugs. 2006, 23-38. https://doi.org/10.1016/S0065-7743(06)41002-2

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    MENDELEY PAIRING EXPIRED
    Your Mendeley pairing has expired. Please reconnect